similar benefits as Glaxo's key drugs.Glaxo's key vaccines Cervarix and Synflorix lost the first-mover advantage to Merck and Pfizer, respectively. Glaxo's next-generation respiratory drugs should help mitigate both branded and generic
By Seeking Early Retirement : This article refers to the German Merck KGaA (OTC: MKGAF ). The more well known U.S. Merck & Co. (NYSE: MRK ) used to be part of Merck in the past, but has been expropriated during the First World War
Merck has informed Oncothyreon (NASDAQ: ONTY ) a randomized Phase 1/2 study of ..... progression free survival, time to progression or time to failure)." Merck has advised Oncothyreon it will "recommend that the investigational treatment
in patients with Secondary Progressive Multiple Sclerosis (SPMS). I also argued that Merck Serono, the biopharmaceutical division of Merck (NYSE: MRK ), which has option and licensing rights to Tcelna, could acquire Opexa at a substantial
WASHINGTON, Aug 13 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co.
Merck KGaA ADR ( OTCPK:MKGAY ) Q2 2014 Results ..... Dear, ladies and gentlemen, welcome to the Merck investor and analyst conference call on second ..... Constantin Fest, Head of Investor Relations at Merck , and I am very happy Complete Story »
WASHINGTON, Aug 13 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co..
The FDA approves Merck 's ( MRK +1.3% ) Belsomra ( suvoexant ) tablets for the treatment of insomnia. Suvoexant is the first orexin receptor antagonist cleared
Merck 's internal research and development has ..... a major threat from generic competition. Merck 's restructured and more focused R&D programs ..... should yield increased productivity. We give Merck KGaA a Standard Stewardship Rating. Since
Merck KGaA reported second-quarter results that ..... our fair value estimate or moat ratings. Merck posted organic growth across all four business ..... 3% and Europe grew less than 1%. While Merck should continue to benefit from market growth